Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
CLINICAL CARDIOLOGY（2023）
Abstract
The OPTIMA-4 trial offers an opportunity to assess the optimal dual antithrombotic regimen in ACS patients with concomitant NVAF after the implantation of new-generation DES.
MoreTranslated text
Key words
acute coronary syndrome,dual antithrombotic treatment,new oral anticoagulants,new-generation drug-eluting stent,nonvalvular atrial fibrillation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined